A Chinese traditional medicines company known as 999 Pharmaceutical is expanding in the USA. It claims to be the biggest company of its kind in mainland China, but the firm has drawn attention to itself in the west more because it was created by the People's Liberation Army and is seeking a Big Board listing, than because of the nature of its business.
Critics in the west are surprised and angered by the military link, particularly relating to the role of the military in dealing with dissenters to the regime in China, and its role in selling arms to countries that the west considers to be some of the world's most belligerent, comments the Wall Street Journal.
The company insists that it is distancing itself from its military connections and it is reported that, in February, 999 raised foreign capital through the sale of 60% of its stock. An Asian affiliate of Citicorp has acquired a 2.49% stake in the company, and 25% of 999 is owned by two US investment companies, Paloma Partners and Tudor Investments Group of New York, reports the WSJ.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze